SCHEMBL6134785

SCHEMBL6134785

CCCCOC1CCN(c2ccc(C(=O)NN)cc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.50
HSD17B10 Q99714 2/20 0.50
HPGD P15428 1/20 0.50
TSHR P16473 1/20 0.50
TAAR1 Q96RJ0 1/20 0.50
ALDH1A1 P00352 4/20 0.48
HIF1A Q16665 1/20 0.48
SMN1; SMN2 Q16637 4/20 0.47
KDM4E B2RXH2 2/20 0.47
LMNA P02545 2/20 0.47
HDAC3 O15379 5/20 0.46
HDAC8 Q9BY41 5/20 0.46
LIPC P11150 1/20 0.45
LIPG Q9Y5X9 1/20 0.45
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
KMT2A Q03164 2/20 0.44
TP53 P04637 1/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6134206 0.96 HDAC3 (0.47) MAPTHSD17B10HPGDTSHRTAAR1
SCHEMBL6132370 0.89 SMYD3 (0.43) MAPTHSD17B10HPGDTSHRTAAR1
SCHEMBL6132500 0.89 SMYD3 (0.43) MAPTHSD17B10HPGDTSHRTAAR1
SCHEMBL6134735 0.89 SMYD3 (0.43) MAPTHSD17B10HPGDTSHRTAAR1
SCHEMBL6133982 0.87 HDAC3 (0.46) MAPTHSD17B10HPGDTSHRTAAR1
SCHEMBL6133632 0.86 HDAC3 (0.48) MAPTHSD17B10HPGDTSHRTAAR1
SCHEMBL19002069 0.85 HRH3 (0.48) MAPTHSD17B10HPGDTSHRTAAR1
SCHEMBL6134525 0.83 HPGD (0.47) MAPTHPGDTSHRALDH1A1SMN1; SMN2
SCHEMBL6134832 0.83 HDAC3 (0.49) MAPTHSD17B10HPGDTSHRTAAR1
SCHEMBL6134505 0.83 GPR119 (0.41) MAPTHSD17B10HPGDTSHRTAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050261177-A1 Compound ASTELLAS PHARMA INC. (JP) 2005-11-24 US disclosed
EP-1366066-A2 CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-12-03 EP disclosed
WO-2002072621-A2 CYCLOHEXAPEPTIDE HAVING ANTIMICROBIAL ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261177-A1 Compound MANBA, MAN2B1, MAN2A1 MAPT 1629/4885HSD17B10 2683/4885HPGD 3433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.